Five hidden risks in early-phase OSD formulation development
Five hidden risks in early-phase OSD formulation development
Early-phase oral solid dose development presents a range of hidden risks that can impact long-term success. From API complexity to scalability and regulatory readiness, thoughtful planning can help mitigate setbacks and keep programs on track.

Added Date:

2025-06-10

Filters:

Filter Category Filter Values
Specialty
  • Other
Month
  • June
Language
  • Japanese
Capability
  • Oral Solid Dose
Year
  • 2025
Asset Type
  • Blog
Country
  • Japan
Region
  • Asia Pacific (APAC)
Market Category
  • Small molecule

Country Availability:


()

Gated Form:

None Set